Latest Trovagene Inc. Stories
SAN DIEGO, Feb. 11, 2015 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) today announced the closing of its previously announced underwritten public offering.
SAN DIEGO, Feb. 10, 2015 /PRNewswire/ -- Trovagene, Inc.
Large-scale study shows potential for non-invasive test to be made available to millions of women worldwide who are unscreened for the detection of cervical cancer SAN DIEGO, Feb.
SAN DIEGO, Feb. 6, 2015 /PRNewswire/ -- Trovagene, Inc.
MOUNTAIN VIEW, Calif., Jan.
Prospective clinical studies to evaluate Trovagene's Precision Cancer Monitoring platform to determine the emergence of resistance mutations using circulating tumor DNA SAN DIEGO,
Trovagene's proprietary KRAS assay enables physicians to determine mutational status, monitor treatment response, and use genomics to aid in predicting patient prognosis SAN DIEGO,
Company expands lung cancer clinical program for its Precision Cancer MonitoringSM solution to up to 700 patients at three leading cancer centers SAN DIEGO, Jan.
Company continues to expand its clinical collaborations with National Comprehensive Cancer Network centers across a broad range of clinically actionable mutations in major cancer types
SAN DIEGO, Jan. 7, 2015 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D.
- A handkerchief.
- In general, any miraculous portrait of Christ.